RZLTRezolute, Inc.
Price
-61%1YEnd-of-day closes, not the intraday tick.
RyuScore
Weak, higher than 3% of companiesThe five questions
2 of 5 availableOnly two of the five can be answered for RZLT today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Watch
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?Mixed
Rezolute, Inc. (“Rezolute”, the “Company”, “we” or “us”) is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (“HI”).
In the company’s own words · 10-K filed Sep 24, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
The next results filing is expected around Dec 24, 2026, a quarter after the last one.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 14, 2026Rezolute Announces Completion of Enrollment.Regulation FD disclosure · press release
- Oct 5, 2026Announces FDA Recommendation to Hold a Pre-BLA.Regulation FD disclosure · press release
- Sep 24, 2026Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.